Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Expedia Group, Inc. stock logo
EXPE
Expedia Group
$135.19
-1.1%
$134.35
$87.94
$160.05
$18.43B1.862.39 million shs975,623 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.63
0.0%
$26.92
$25.20
$40.37
$145.13B0.6141.71 million shs18.64 million shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Expedia Group, Inc. stock logo
EXPE
Expedia Group
+0.71%+3.85%-0.79%-9.93%+45.44%
Pfizer Inc. stock logo
PFE
Pfizer
+0.98%-2.32%-7.57%-5.07%-34.04%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Expedia Group, Inc. stock logo
EXPE
Expedia Group
4.6318 of 5 stars
3.22.00.01.73.22.53.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9785 of 5 stars
3.23.04.24.83.11.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Expedia Group, Inc. stock logo
EXPE
Expedia Group
2.48
Hold$149.1210.30% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3341.76% Upside

Current Analyst Ratings

Latest PFE and EXPE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$175.00 ➝ $175.00
4/18/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$130.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/19/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$150.00 ➝ $145.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/23/2024
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$36.00
2/9/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$115.00 ➝ $136.00
2/9/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$155.00
2/9/2024
Expedia Group, Inc. stock logo
EXPE
Expedia Group
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$159.00 ➝ $155.00
(Data available from 4/30/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Expedia Group, Inc. stock logo
EXPE
Expedia Group
$12.84B1.44$20.00 per share6.76$20.44 per share6.61
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.48$3.00 per share8.53$15.81 per share1.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Expedia Group, Inc. stock logo
EXPE
Expedia Group
$797M$5.3825.1310.760.426.21%35.79%4.61%5/2/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3671.199.251.143.62%10.88%4.91%5/1/2024 (Confirmed)

Latest PFE and EXPE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Expedia Group, Inc. stock logo
EXPE
Expedia Group
-$0.3680N/A+$0.3680N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
2/8/2024Q4 2023
Expedia Group, Inc. stock logo
EXPE
Expedia Group
$1.08$1.18+$0.10$1.44$2.88 billion$2.89 billion
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Expedia Group, Inc. stock logo
EXPE
Expedia Group
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.55%+2.57%466.67%15 Years

Latest PFE and EXPE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Expedia Group, Inc. stock logo
EXPE
Expedia Group
2.24
0.78
0.78
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Expedia Group, Inc. stock logo
EXPE
Expedia Group
90.76%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Expedia Group, Inc. stock logo
EXPE
Expedia Group
8.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Expedia Group, Inc. stock logo
EXPE
Expedia Group
17,100136.29 million125.29 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

PFE and EXPE Headlines

SourceHeadline
7 Safe Haven Stocks That Can Withstand the Markets Worst Meltdowns7 Safe Haven Stocks That Can Withstand the Market's Worst Meltdowns
investorplace.com - April 30 at 1:50 PM
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
zacks.com - April 30 at 12:21 PM
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 EarningsPfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
benzinga.com - April 30 at 12:01 PM
FDA approves Labcorp companion diagnostic for Pfizer gene therapyFDA approves Labcorp companion diagnostic for Pfizer gene therapy
finance.yahoo.com - April 30 at 9:54 AM
5 Top Stocks to Buy in May5 Top Stocks to Buy in May
fool.com - April 30 at 7:45 AM
Why Im Buying This Beaten-Down, High-Yield Dividend Stock Hand Over FistWhy I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
fool.com - April 30 at 5:50 AM
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks InsteadForget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
fool.com - April 30 at 5:06 AM
Pfizer Showcases Advancements in Breakthrough Cancer Treatments at ASCO 2024 Annual MeetingPfizer Showcases Advancements in Breakthrough Cancer Treatments at ASCO 2024 Annual Meeting
indiaeducationdiary.in - April 30 at 4:53 AM
Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?Is 7%-Yielding Pfizer Stock A Buy On The Dip Before Q1?
seekingalpha.com - April 30 at 4:53 AM
Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical CancerPfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer
markets.businessinsider.com - April 29 at 11:47 PM
Van ECK Associates Corp Raises Position in Pfizer Inc. (NYSE:PFE)Van ECK Associates Corp Raises Position in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 29 at 8:49 PM
These 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To ClimbThese 3 High-Yield Stocks Have Been Growing Their Dividends Non-Stop, And Analysts Expect Their Share Prices To Climb
finance.yahoo.com - April 29 at 6:46 PM
UPDATE 1-US FDA grants full approval for Pfizers cervical cancer drugUPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug
finance.yahoo.com - April 29 at 6:46 PM
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - April 29 at 6:46 PM
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - April 29 at 6:46 PM
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
businesswire.com - April 29 at 6:40 PM
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
businesswire.com - April 29 at 6:40 PM
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
globenewswire.com - April 29 at 6:40 PM
US FDA grants full approval for Pfizers cervical cancer drugUS FDA grants full approval for Pfizer's cervical cancer drug
reuters.com - April 29 at 4:09 PM
Pfizer (NYSE:PFE) Trading Up 1.3%Pfizer (NYSE:PFE) Trading Up 1.3%
marketbeat.com - April 29 at 3:17 PM
These Pharmaceutical Firms Are On Sale: Abbvie, Pfizer, And GileadThese Pharmaceutical Firms Are On Sale: Abbvie, Pfizer, And Gilead
msn.com - April 29 at 1:46 PM
Pfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dosePfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose
bizjournals.com - April 29 at 1:46 PM
Heres How to Play Pfizer (PFE) Stock Ahead of Q1 EarningsHere's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
zacks.com - April 29 at 1:16 PM
Why Pfizer (PFE) is a Top Value Stock for the Long-TermWhy Pfizer (PFE) is a Top Value Stock for the Long-Term
zacks.com - April 29 at 10:46 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Expedia Group logo

Expedia Group

NASDAQ:EXPE
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through B2C, B2B, and trivago segments. Its B2C segment includes Brand Expedia, a full-service online travel brand offers various travel products and services; Hotels.com for lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz, Travelocity, Wotif Group, ebookers, CheapTickets, Hotwire.com and CarRentals.com. The company's B2B segment provides various travel and non-travel companies including airlines, offline travel agents, online retailers, corporate travel management, and financial institutions who leverage its travel technology and tap into its diverse supply to augment their offerings and market Expedia Group rates and availabilities to its travelers. Its trivago segment, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. In addition, the company provides brand advertising through online and offline channels, loyalty programs, mobile apps, and search engine marketing, as well as metasearch, social media, direct and personalized traveler communications on its websites, and through direct e-mail communication with its travelers. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.